← feed

Is NCT02603445 results overdue?

Yes — results are overdue. Primary completion was 2018-07-10; the FDAAA-801 reporting deadline (2019-07-10) passed 2631 days ago and no results are posted on ClinicalTrials.gov.

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

NCT IDNCT02603445 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-07-10 (ACTUAL)
Reporting deadline2019-07-10 (completion + 365d)
Days overdue2631
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-09-22 · SHA-256 ba68bac459cb2e9f… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02603445. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →